OrbusNeich Medical Group Holdings Limited Announces Robust FY2025 Results, Expansion Strategies, and Dividend Increase

Highlights of FY2025 Annual Results and Strategic Developments

OrbusNeich Medical Group Holdings Limited (“OrbusNeich”), a leading multinational medical device company specializing in interventional devices for PCI and PTA procedures, has released its annual results for the year ended December 31, 2025. The company delivered record financial performance, continued global expansion, and announced significant changes to its use of listing proceeds, all of which may be highly relevant to shareholders and could impact share valuation.

Key Financial Results

• Record Revenue & Profit: Revenue reached US\$180.5 million, marking a 10.0% year-on-year increase. Net profit attributable to shareholders rose 5.5% to US\$41.9 million. Core operating profit surged 20.2% to US\$34.8 million.
• Strong Sales Growth: Sales volume hit a new high of 2.02 million units (+16.2% YoY), with proprietary products up 13.1% and third-party products up 34.9%.
• Dividend Increase: Final dividend proposed at HK12 cents per share (up 20% from 2024), plus a special dividend of HK15 cents per share paid in October 2025 to commemorate the company’s 25th anniversary.
• Gross Margin & Net Margin: Gross margin decreased slightly to 67.8% (from 69.8%), and net profit margin was 23.2% (down from 24.2%) due to pricing pressure in China and sales mix shifts.
• Cash Position: The Group maintained a robust financial position with US\$228.7 million in cash and bank balances, providing flexibility for acquisitions and facility expansion.

Business and Market Updates

• Global Expansion: Direct sales teams established in 12 markets, including Hong Kong, Taiwan, Japan, Indonesia, Malaysia, Singapore, Germany, France, Switzerland, Spain, Monaco, and the Netherlands. Plans underway to expand direct sales into Belgium in 2026.
• APAC Region: Revenue grew 15.7% to US\$60.5 million, driven by expansion in Indonesia, Malaysia, Singapore, Hong Kong, and new direct sales in Taiwan.
• EMEA Region: Revenue increased 19.6% to US\$46.9 million, with direct sales markets (Germany, France, Spain) growing over 20% and distributor markets (Saudi Arabia, Slovakia, Czech Republic, UK) also performing strongly.
• US Market: Revenue soared 37% to US\$21.2 million, as tariff impacts eased and product demand grew, especially for coronary and peripheral balloons.
• China Market: Despite higher sales volume, revenue fell 13.9% to US\$17.8 million due to lower average selling prices from volume-based procurement (VBP) schemes.
• Japan: Scoreflex QUAD received PMDA approval and launched in Q4 2025, narrowing sales decline to 6.2% YoY, with revenue at US\$32.3 million.

Operational and Strategic Developments

• Product Pipeline & R&D: Over 220 patents and 55 approved products globally. Major regulatory approvals obtained for new products in Japan, Europe, and China. Multiple applications pending with FDA, PMDA, and NMPA, including for Teleport Glide, Sapphire ULTRA, JADE PLUS, and drug-coated balloons.
• Clinical Trials: US clinical trial for Sapphire 3 completed patient enrollment. TricValve clinical trials accelerated in China and US (FDA IDE trial approved), with commercial implantation in Greater Bay Area in July 2025.
• Production Capacity: Aggregate annual production capacity reached 2.1 million units. Construction of a new R&D and manufacturing facility in Hangzhou, PRC, to add 2.4 million units capacity by 2027.
• Third-Party Product Collaboration: Strengthened partnership with SonoScape Medical Corp. for IVUS product distribution in APAC and EMEA direct sales markets, with sales initiated in Hong Kong, Malaysia, Germany, Spain.

Financial Review & Capital Management

• Cost of Sales: Increased 16.9% to US\$58.0 million, reflecting higher sales volume.
• Operating Expenses: Selling and distribution expenses rose 13.5% to US\$42.5 million due to sales team expansion and acquisition in Taiwan. General and administrative expenses decreased 1.5% to US\$24.9 million. R&D expenses fell 7.7% to US\$15.7 million.
• Effective Tax Rate: Increased from 6.0% to 10.7%, driven by profit growth and reduced deferred tax assets.
• Liquidity: Current ratio at 10.5x, net current assets at US\$317.4 million, and no significant contingent liabilities or hedging contracts.

Changes in Use of Proceeds

• Reallocation of Listing Proceeds: As of December 31, 2025, US\$13.9 million unutilized proceeds will be reallocated primarily to expanding the R&D team in Shenzhen and construction/renovation of new facilities acquired in 2023. This change is intended to optimize resource deployment and does not materially affect the Group’s business nature.

Corporate Governance & Shareholder Information

• Corporate Governance: The Board continues to uphold high standards, with a strong independent element. Mr. David Chien serves as both Chairman and CEO due to his industry experience.
• Dividends: Shareholders approved the final dividend at the AGM held on June 8, 2026, payable on or around June 26, 2026. Record dates for dividend and AGM eligibility are specified.
• Share Buyback: 560,000 shares acquired for share award schemes in 2025 at a total cost of US\$308,000.
• Employee Update: Total employees increased to 1,477, with US\$65.0 million spent on staff remuneration and training.

Outlook and Potential Price-Sensitive Information

• Accelerated Overseas Growth: Expected continued revenue growth in 2026, driven by new product launches, expanded third-party partnerships, and further transition to direct sales in Europe (Netherlands, Belgium).
• China Market Recovery: Despite short-term pricing pressure from VBP, Group expects PRC sales volume and revenue to regain momentum as PCI procedures increase and scoring balloons are included in new VBP programs.
• Product Launches & Acquisitions: Multiple proprietary and third-party products slated for launch in Japan and Europe. Ongoing negotiations and potential downstream acquisitions in Europe to consolidate brand and expand product portfolio.
• Financial Flexibility: Strong cash reserves ensure ability to fund further acquisitions, new facilities, and continued dividend payouts.

Important Information for Shareholders

• Dividend Increase and Special Dividend: Higher final dividend and special dividend may positively impact share price and investor sentiment.
• Reallocation of Listing Proceeds: Strategic change in use of proceeds towards R&D and facility expansion reflects management’s focus on long-term growth.
• Global Expansion & M&A Activity: Ongoing direct sales expansion and potential acquisitions in Europe may be price sensitive and drive future revenue and margin growth.
• Product Pipeline Progress: Multiple regulatory approvals and clinical trials underway. Timely product launches could boost revenue and market share.
• Operational Risks: Currency fluctuations, VBP pricing pressure in China, and interest rate changes may impact margins and earnings.

Conclusion

OrbusNeich Medical Group Holdings Limited continues to demonstrate robust financial and operational performance with accelerating global expansion, a rich product pipeline, and prudent capital management. The company’s dividend increase, strategic reallocation of listing proceeds, and ongoing acquisition and product development activities may significantly impact shareholder value and share price in the near and medium term. Investors should closely monitor the progress of new product launches, regulatory approvals, China market recovery, and any acquisition activity as potential catalysts for future share price movement.

Disclaimer: This article is based on the official annual results and management discussion released by OrbusNeich Medical Group Holdings Limited for FY2025. The information contained herein is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors prior to making any investment decisions. The company’s future performance is subject to risks and uncertainties, including but not limited to market conditions, regulatory changes, and operational risks.

View ORBUSNEICH Historical chart here